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Proposition of a new scale for the harmonization and normalization of the nAPCsr: a 
scientific and regulatory need for clinical studies comparison
BACKGROUND
v The evaluation of the activated protein C resistance assay based on the endogenous
thrombin potential (ETP-based APCr assay) is requested during the development of
steroid contraceptives.1
v Results are usually expressed as “normalized APC sensitivity ratio” (nAPCsr) which
is the ratio of the patient’s sample on a reference plasma regarding the inhibitory
sensitivity of the ETP towards exogenous APC.2,3
v The reference plasma should achieve near 10% residual ETP in the presence of
exogenous APC.
v However, the use of homemade reference plasma makes the nAPCsr difficult to
compare between studies and the impossibility to obtain exactly 10% residual ETP,
because of the inter-assay variability, can significantly affect the theoretical 0 to 10
scale of nAPCsr.
METHOD
v 790 individual plasmas (issued from two sponsored clinical trials) were analyzed to
compared their nAPCsr and nAPCsr10
v Measurements were performed following our validated protocol of the ETP-based
APCr assay.
v A commercially available reference plasma and three levels of quality controls
(QCs) were used to validate each experiment.
v Results were expressed as nAPCsr [▶ equation 1] and as nAPCsr10 [▶ equation 2]
§ nAPCsr = !"#$%&' ()* (,-*.) "#$%&' ()* (0-*.)!1'2'3'45' %&#6$# ()* (,-*.) 1'2'3'45' %&#6$# ()* (0-*.) [equation 1]
§ nAPCsr10=
789:;< =<>?@A8; BCD (%)FG% [equation 2]
with residual ETP % = 789:;< BCD HIDJ789:;< BCD KIDJ
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AIM
To compare the nAPCsr with this new method for calculation of APC resistance: the
nAPCsr10.
CONCLUSION
This is the first study presenting a new scale for the harmonization and
normalization of the nAPCsr.
Results revealed a better reproducibility with the nAPCsr10. It avoids the
additional variability and the unharmonized scale brought by the use of a
reference plasma. Instead, this reference plasma can serve as an additional level of
control targeting the desired 10% of residual activity.
This new method and result expression will provide the pharmaceutical industry,
the regulatory bodies and the physician, with the opportunity of better
reproducibility and harmonization. This will definitively help in study-to-study
comparison.
This standardized expression could ease the establishment of thresholds to assess
patient’s thrombotic state according to his resistance to APC.
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FIGURE 1: Correlation between nAPCsr and
nAPCsr10. Spearman correlation coefficient (rs)
[95% CI] of 0.9896 [0.9880-0.9910]; p-value<0.0001;
r2 for linear regression = 0.9704. Linear regression
(red straight line) with a slope [95% CI] of 0.9334
[0.9220-0.9448] (blue dotted lines) and Y-intercept
of 0.02630.
FIGURE 2: Derived Bland-
Altman analysis between
nAPCsr and nAPCsr10 for the
measurement of APC
resistance in plasma samples.
Differences (nAPCsr10-
nAPCsr) are expressed as a
percentage of nAPCsr10. The
red dotted line represents the
mean difference and blues
dotted lines represent 95% IC
[=1.96*SD].
A. Test performances
v Over 86 measurements (38 with batch 1 and 48 with batch 2), no statistically
significant difference (p-value>0.05) was observed between the two batches of
reference plasma.
v QCs fitted into their acceptability ranges regardless the batch used but nAPCsr was
less reproducible (higher SD) than nAPCsr10. [▶Table 1]
nAPCsr nAPCsr10
Mean SD 95% CI Mean SD 95% CI
QC 
high
Batch 1 8.80 0.75 [7.32-10.28] 9.37 0.27 [8.85-9.90]
Batch 2 8.88 0.90 [7.11-10.64] 9.39 0.23 [8.94-9.84]
QC 
interm
Batch 1 7.51 0.49 [6.55-8.47] 8.01 0.29 [7.44-8.59]
Batch 2 6.46 0.49 [5.50-7.42] 6.86 0.40 [6.07-7.65]
QC 
low
Batch 1 0.00 / / 0.00 / /
Batch 2 0.00 / / 0.00 / /
TABLE 1: Range values of the nAPCsr and the nAPCsr10 among the two batches of reference plasma on
QC high, QC intermediate (QC int.) and QC low. The mean, standard deviation (SD) and 95% confidence
interval (=1.96*SD) for each batch on the three levels of QC are shown.
B. Correlation between nAPCsr and nAPCsr10
v Wilcoxon signed-rang paired showed a statistically significant difference between
nAPCsr and nAPCsr10.
v Nonetheless, a correlation between nAPCsr and nAPCsr10 was demonstrated with
a Spearman correlation (rs) coefficient of 0.99 (95%CI: 0.9880-0.9910; p-
value<0.0001).
v Linear regression showed a slope of 0.93 which denoted 7% downward systematic
deviation of nAPCsr compared to nAPCsr10. [▶ Figure 1]
v Bland-Altman analysis confirmed our statement that nAPCsr underestimated APC
resistance compared to nAPCsr10 with a mean difference (nAPCsr10-nAPCsr) of
5.64% compared to nAPCsr10. [▶ Figure 2]
v As mean residual ETP ratio of the refence plasma was greater than 0.1 (0.107), when
used at the denominator, it gave smaller values than if we had 0.1 at the
denominator as for the nAPCsr10.
v Mean inhibition % of the reference plasma (both batches mixed) was 89.30% (SD:
1.03%, 95% CI: [87.29%-91.31%]) and expressed in ratio, it equalled 0.107 (95% CI:
0.087-0.127].
v Despite a weak variability of the reference plasma, the nAPCsr scale could vary
widely.
v In the case of inhibition % of the reference plasma equalled to 91.8 (maximal
tolerated limit in our study [mean inhibition % + 2.5%]), residual ETP ratio would be
0.082. Therefore, nAPCsr scale could go up to 12.2 instead of the maximal value of 10
that is theoretically proposed.
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